 |  |
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISAâ„¢ technology.
FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gates Ventures today announced a strategic partnership with the goal to generate one of the largest proteomic datasets linked to clinical outcomes in Alzheimer's Disease (AD). This international project will profile over 40,000 plasma samples representing AD and related dementias using Alamar's ultra-sensitive NULISAâ„¢ technology, with the goal of accelerating biomarker discovery and driving new insights into the progression and treatment of AD.
"This collaboration reflects our shared commitment to transform the landscape of Alzheimer's research through data, technology, and global partnerships," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform with Alzheimer's Disease Data Initiative's infrastructure and Gates Venture's mission-driven investment, we aim to catalyze a new era of biomarker-driven discovery and therapeutic development."
As part of the initiative, Alamar's NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 will be implemented at research centers in the United States, Sweden, United Kingdom, and India. These panels deliver unparalleled sensitivity and specificity, enabling the accurate measurement of hundreds of brain- and immune-related proteins from just a small volume of blood or cerebrospinal fluid. A key feature of the CNS panel is its unique ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in blood—a critical advancement for the development of community-based screening programs. The resulting proteomic data will be integrated with clinical and longitudinal outcome measures and shared with the global research community by leveraging the Global Neurodegeneration Proteomics Consortium's (GNPC) secure data-sharing processes.
"Understanding the biological underpinnings of Alzheimer's Disease is essential for developing effective treatments," said Niranjan Bose, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative. "This initiative will provide a rich resource to researchers worldwide and help overcome long-standing barriers in early detection and stratified interventions."
This initiative represents a major step forward in building a comprehensive, clinically annotated Alzheimer's plasma proteome atlas, with the potential to unlock new biomarkers for diagnosis, prognosis, and therapeutic response. This strategic collaboration complements the efforts of the GNPC, which has brought together top dementia researchers and datasets to collaborate and create one of the largest disease-specific proteomics datasets ever assembled. The project also emphasizes inclusivity by incorporating diverse cohorts from multiple geographic and ethnic populations.
About the Alzheimer's Disease Data Initiative
The Alzheimer's Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures for Alzheimer's disease and related dementias. Learn more about the Alzheimer's Disease Data Initiative at www.alzheimersdata.org.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGOâ„¢ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISAâ„¢ technology.
FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gates Ventures today announced a strategic partnership with the goal to generate one of the largest proteomic datasets linked to clinical outcomes in Alzheimer's Disease (AD). This international project will profile over 40,000 plasma samples representing AD and related dementias using Alamar's ultra-sensitive NULISAâ„¢ technology, with the goal of accelerating biomarker discovery and driving new insights into the progression and treatment of AD.
"This collaboration reflects our shared commitment to transform the landscape of Alzheimer's research through data, technology, and global partnerships," said Yuling Luo, PhD, Founder, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform with Alzheimer's Disease Data Initiative's infrastructure and Gates Venture's mission-driven investment, we aim to catalyze a new era of biomarker-driven discovery and therapeutic development."
As part of the initiative, Alamar's NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 will be implemented at research centers in the United States, Sweden, United Kingdom, and India. These panels deliver unparalleled sensitivity and specificity, enabling the accurate measurement of hundreds of brain- and immune-related proteins from just a small volume of blood or cerebrospinal fluid. A key feature of the CNS panel is its unique ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in blood—a critical advancement for the development of community-based screening programs. The resulting proteomic data will be integrated with clinical and longitudinal outcome measures and shared with the global research community by leveraging the Global Neurodegeneration Proteomics Consortium's (GNPC) secure data-sharing processes.
"Understanding the biological underpinnings of Alzheimer's Disease is essential for developing effective treatments," said Niranjan Bose, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative. "This initiative will provide a rich resource to researchers worldwide and help overcome long-standing barriers in early detection and stratified interventions."
This initiative represents a major step forward in building a comprehensive, clinically annotated Alzheimer's plasma proteome atlas, with the potential to unlock new biomarkers for diagnosis, prognosis, and therapeutic response. This strategic collaboration complements the efforts of the GNPC, which has brought together top dementia researchers and datasets to collaborate and create one of the largest disease-specific proteomics datasets ever assembled. The project also emphasizes inclusivity by incorporating diverse cohorts from multiple geographic and ethnic populations.
About the Alzheimer's Disease Data Initiative
The Alzheimer's Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures for Alzheimer's disease and related dementias. Learn more about the Alzheimer's Disease Data Initiative at www.alzheimersdata.org.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGOâ„¢ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.
Over 15,000 visitors to the INCHEON–IFEZ Booth; IFEZ supported a record 50 innovation companies participating in CES 2026.
Participating companies secure a foundation for global expansion, including 20 MoU signings.
INCHEON, South Korea, Jan. 16, 2026 /PRNewswire/ -- The Incheon Free Economic Zone (IFEZ) announced the successful operation of the INCHEON–IFEZ Booth at CES 2026, presenting IFEZ's future-city vision and the technologies of Incheon-based innovators to a global audience.
Under the theme "Destination Incheon — From Smart City to AI City," the booth highlighted a sustainable urban future enabled by Incheon companies' innovations and drew more than 15,000 visitors, according to IFEZ.
During CES 2026, IFEZ also met with the Fairfax County Economic Development Authority (FCEDA) to discuss support measures and collaboration models for helping Incheon startups enter the U.S. market. The two sides plan to develop practical joint programs through continued cooperation.
IFEZ supported a record 50 companies at CES 2026 across multiple participation tracks, dividing them across various exhibition areas: 10 companies in the 'INCHEON-IFEZ' Booth at the Las Vegas Convention Center, 10 in the Korea pavilion (KOTRA) at the Eureka Park, 6 in the Global Pavilion, and 15 as the Incheon Startup Park Delegation and 10 Innovation Award showcase participants.
These companies achieved record-breaking results, conducting 1,419 business consultations with overseas buyers and investors, with the estimated value of export consultations reaching $560 million—more than 400 additional meetings compared to last year. In addition, nine companies signed 20 MOUs, building momentum for global expansion and investment opportunities.
Leadpoint System, a smart manufacturing and industrial automation solutions provider, signed an MOU with Webtronic Labs, a U.S.-based technology R&D company.
emCT, which specializes in fire detection and safety management solutions, signed an MOU with Texas Legacy Realty, a Texas-based real estate development and operations company, to pursue collaboration on applying fire safety and "safe zone" solutions in commercial and residential buildings.
Medicell Healthcare, a regenerative medicine and bio-healthcare solutions company, signed an MOU with the City of Phoenix, Arizona's largest city, and discussed cooperation on technology collaboration and local proof-of-concept initiatives in public healthcare.
IFEZ said 14 supported companies earned 17 CES Innovation Awards, the highest total to date for Incheon, drawing strong interest from global buyers and investors. Deep Fusion AI received a Best of Innovation honor for its radar-based sensor-fusion AI technology, gaining attention in next-generation autonomous driving and robotic perception.
Mayor Yoo Jeong-bok said the CES participation advanced the Incheon–IFEZ AI City vision on the global stage and pledged continued support to expand Incheon companies' international reach and strengthen Incheon as a global business hub.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
INCHEON-IFEZ Booth Wraps Up a Successful CES 2026, Recording $560M in Export Consultations and 17 Innovation Awards
